Baxter International Inc (BAX)
割安ファンダメンタル
41
株価
$23.77
時価総額
$12.14B
パート1 · 企業の価値
概要
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
ICU Medical sells IV solutions, infusion pumps and administration sets to the same US hospital pharmacies and supply contracts that Baxter's Medical Products & Therapies segment depends on.
BD competes head-on with Baxter for hospital infusion contracts with its Alaris smart pumps, IV sets and injectable drug delivery lines.
Stryker is the closest rival to Baxter's Hillrom business for smart hospital beds, patient monitoring and operating-room equipment bought by the same acute-care hospitals.
The German family-owned group offers the same sterile IV fluids, infusion pumps and parenteral nutrition range, and is Baxter's main rival for European hospital tenders.
Fresenius Kabi competes with Baxter both in IV fluids and parenteral nutrition and in specialty injectable generics sold to hospital pharmacies.
貸借対照表と流動性
売上高
$11.47B
直近12か月（2026/6/30まで）
純利益
$-1.06B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$332M
自己資本合計
$6.13B
負債合計
$13.95B
流動比率
1.95
利払い倍率
0.93
負債/EBITDA
0.31
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$64.96
現在株価
$23.77
安全マージン
+63.4%
適正価値レンジ
$42.22 - $87.69
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
-15.6%
P/B レシオ
1.97
P/FCF
36.58
粗利益率
30.1%
ROIC
-1.3%
収益性レーダー
価値創造（経済的モート）
ROIC
-1.3%
WACC
8.3%
ROIC − WACC
-9.6 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（10）
- Gross Margin 30.1%
- P/B Ratio 1.97
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Earnings Surprise avg 15.7%
- Share Dilution 0.1%
- Piotroski F-Score 6/9
不合格（13）
- EPS shows upward trend
- Price CAGR -6.03%
- ROIC -1.3%
- P/FCF 36.58
- Operating Margin -2.4%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -16.6%
- Revenue Growth 5Y -0.8%
- Analyst Consensus 25% Buy
- Net Margin Trend -9.3% vs -1.4%
データなし（4）
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
低品質：会計処理を調査してください
株式希薄化
株式数は安定している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Andrew P. Hider | CEO, President, Interim Group President of Medical Products & Therapies and Director | 48 |
| Mr. David S. Rosenbloom | Executive VP & General Counsel | 65 |
| Ms. Maria Soriano | Group President of Infusion Therapies & Platforms | - |
| Ms. Anita A. Zielinski | Interim CFO, Senior VP, Chief Accounting Officer & Controller | 52 |
| Mr. Charles Patel | Senior VP & Chief Information Officer | 55 |
| Mr. Kevin Moran | Vice President & Head of Investor Relations | - |
| Ms. Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | - |
| Ms. Cynthia Carlisle | Executive VP & Chief Human Resources Officer | 50 |
| Mr. James W. Borzi | Executive VP & Chief Supply Chain Officer | 62 |
| Mr. Steven P. Wallace | President of Advanced Surgery & Commercial Excellence | 45 |
監査リスク
3
取締役会リスク
2
報酬リスク
9
株主権利リスク
2
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for BAX, sourced from Markets Gazette.